Approved Use: Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
- Prescribing information
- Patient Product Information
- Instructions for use
- Approved Use
How to Process a Claim
Welcome! You've come to the right place to learn how to process a copay claim for Aimovig® (erenumab-aooe).
Still have questions about claims processing? Call the SS&C Health Help Desk at 844-373-0987.
Are you a patient? See our Patient FAQs.
How do I process a claim?
To process claims for patients with commercial coverage, enter the Aimovig® Copay Card prior to running the claim.
If patient with commercial coverage is approved ➔ Copay Offer (i.e. Code 08): Submit the claim to the primary Third-Party Payer first, then submit the balance due to SS&C Health as a Secondary Payer with patient responsibility amount and a valid Other Coverage Code (OCC) of 08. The patient is responsible for the first $5 and reimbursement will be received from SS&C Health up to the maximum limits for the program.
The Aimovig® Copay Card is not valid for any patient uninsured or receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program (e.g. Medicare).
**PLEASE NOTE: Every pharmacy has different systems and procedures. For any questions, the pharmacist or pharmacy tech can call the AimAlly™ Support Team at 833-AIMOVIG (833-246-6844), Monday – Friday, 8 am – 9 pm ET.
How do I enroll a patient in the Aimovig® Copay Card Program?
Patients must enroll themselves at www.aimovigcopaycard.com. They may do this on their desktop or mobile device. If the patient is unable to enroll online, they may call 833-AIMOVIG (833-246-6844). If a patient is eligible, they’ll instantly receive a card enrollment confirmation notice (the enrollment approval page that contains the patient and pharmacist instructions), which they can print and take to the pharmacy today with their prescription and insurance card. A copy of the Aimovig® Copay Card will also be emailed to them upon successful enrollment.